Los Angeles-Area Myeloma Care

A National Cancer Institute-designated comprehensive cancer center, City of Hope^® has been named one of America's top cancer hospitals by U.S. News & World Report for nearly two decades. Through our cancer experts in Duarte, California, as well as Phoenix, Chicago and Atlanta, our blood cancer experts offer leading-edge care and treatments for myeloma. City of Hope is among a dozen national centers that treat myeloma with a multidisciplinary team solely focused on this type of cancer. City of Hope’s approach to treating myeloma starts with a coordinated, multidisciplinary care team, comprising myeloma specialists, whose main goals are controlling your disease so that you can live longer and maintain an active life.

Treatment for myeloma and multiple myeloma is rapidly advancing, and with the approval of new agents, survival rates for myeloma patients are on the rise. As a comprehensive cancer center, City of Hope is at the forefront of that progress. We were involved in pivotal early trials of two drugs — daratumumab and ixazomib — that are now part of myeloma therapy worldwide.

City of Hope's Los Angeles-area myeloma experts provide leading-edge care and perform innovative research to understand the disease better and tailor each patient's treatment to their goals and myeloma type. Our team combines deep experience and diverse perspectives to arrive at the ideal treatment for each patient. Each myeloma patient's care includes regular interaction and input from hematologists, oncologists, radiologists, pathologists, nurses, social workers and specially trained support staff. Our survivorship clinics support and monitor patients throughout and after treatment.

At City of Hope, we are committed to making a difference in the lives of our patients by developing curative therapies that may play a role in treatment. Our goal is to slow down the disease progression, extend remission time and reduce symptoms. We offer access to dozens of clinical trials and new therapies not always available elsewhere.

• Our experienced doctors specialize in treating high-risk or relapsed myeloma and those who have undergone failed therapies.
• We prioritize quality of life by minimizing drug toxicity and tailoring therapy to include medications that deal with common disease-related bone problems.
• Our Judy and Bernard Briskin Center for Multiple Myeloma Research is among the largest programs of its kind in California. We lead the development of over 15 active clinical trials for all multiple myeloma stages and aim to make multiple myeloma and related light-chain amyloidosis manageable and nonlethal through immunotherapy and rational combinatorial therapies.
• Our Kenneth Goldman and Briskin Family Clinical Trials Program offers promising therapies — gene, CAR T cell, and antibody — as part of our ongoing clinical trials aimed at identifying even more effective immunotherapy treatments, including exciting advances in CAR T cell therapy, checkpoint inhibitors, bispecific antibodies and novel antibody-drug conjugates.
• We are home to one of the most prominent U.S. blood stem cell and bone marrow transplant centers, and our innovative approaches include combining transplantation with new therapies. Our highly trained nurses offer outpatient support for bone marrow transplant patients.
• Our research focuses on new drugs and drug combinations that target and attack relapsed myeloma that has become resistant to first-line treatment.
• We customize genetic testing and drug therapy to the molecular profile of specific myeloma types, using computer models to predict toxicity and tailor treatments for efficacy and fewer side effects.
• Our collaborative approach, combined with our dedication to advancing cancer care, results in superior myeloma cancer survival outcomes compared to Los Angeles SEER registry data.

City of Hope consistently ranks among U.S. News and World Report’s list of best hospitals for cancer in the United States, with consecutive rankings for nearly two decades. 

In addition, U.S. News rated City of Hope Duarte as “high performing” for myeloma treatment.